Fmoc-HoCit-OH

Catalog No. :
ACBCES562
CAS No. :
201485-17-8
Molecular Formula :
C22H25N3O5
Molecular Weight :
411.46

IUPAC Name:N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-carbamoyl-L-lysine

Fmoc-HoCit-OH structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g97%$74.00Login to see priceIn stockIn stock
10g97%$147.00Login to see priceIn stockIn stock
25g97%$177.00Login to see priceIn stockInquiry
100g97%$680.00Login to see priceIn stockInquiry
500g97%$2584.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameFmoc-HoCit-OH
IUPAC NameN2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-carbamoyl-L-lysine
MDL No.MFCD00237387
Molecular FormulaC22H25N3O5
Molecular Weight411.46
SMILESO=C(O)[C@@H](NC(OCC1C2=C(C3=C1C=CC=C3)C=CC=C2)=O)CCCCNC(N)=O
InChI KeyVJZUCXPETVPQIB-IBGZPJMESA-N
Synonym201485-17-8 | Fmoc-HoCit-OH | Fmoc-L-homocitrulline | Fmoc-Homocit-OH | (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-6-ureidohexanoic acid | (2S)-6-(carbamoylamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid | L-Lysine, N6-(aminocarbonyl)-N2-[(9H-fluor
CAS No.201485-17-8
PubChem CID7019813

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACBCES562 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEFWU937 route compound structure diagram
    ACEFWU9371190-49-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBCES562 route product structure diagram
    ACBCES562201485-17-8 In Stock
Inquiry

2. ACBCES562 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBCES562 route product structure diagram
    ACBCES562201485-17-8 In Stock
Inquiry

Comments (0)